• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of temozolomide resistance mechanism which is not involved in MGMT in malignant glioma

Research Project

Project/Area Number 22591617
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Cerebral neurosurgery
Research InstitutionKagoshima University

Principal Investigator

YASHIRO Kazutaka  鹿児島大学, 医歯学総合研究科, 客員研究員 (20264418)

Co-Investigator(Kenkyū-buntansha) ARITA Kazunori  鹿児島大学, 医歯学総合研究科, 教授 (90212646)
HIRANO Hirofumi  鹿児島大学, 医学部・歯学部附属病院, 講師 (00264416)
FURUKAWA Tatsuhiko  鹿児島大学, 医歯学総合研究科, 教授 (40219100)
Project Period (FY) 2010 – 2012
Project Status Completed (Fiscal Year 2012)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords膠芽腫 / temozolomide / 耐性 / MLH1 / ABC トランスポーター / glioblastoma / temozolomide resistance / DEC2 / 薬剤耐性
Research Abstract

Treatment with the alkylating agent temozolomide (TMZ) has resulted in benefits for patients with glioblastoma (GBM). Nevertheless, almost all GBMs recur and lead to death of the patient. It is therefore critically important to determine the mechanisms of acquisition of TMZ resistance. Methods:To analyze the mechanism of TMZ-resistance of gliomas, we isolated three TMZ-resistant human glioma U251 cell lines. We examined mRNA expression of mismatch repair (MMR) componentsof the TMZ-resistant cells and evaluated the expression of MutL homolog 1 (MLH1) , with immunohistochemically in GBM specimens obtained from patients who had undergone total or subtotal tumor removal and who suffered from recurrence during administration of TMZ. Results: We found that MLH1 mRNA and protein expression was decreased in all three independent TMZ-resistant cell lines compared to the parental cells and that knock-down of MLH1 expression decreased the TMZ sensitivity of the parent cells. Moreover MLH1 expression was reduced in the recurrent human GBMs during administration of TMZ compared to the level in the initial tumor. Conclusions:We conclude that U251 glioma cells acquire resistance to TMZ by reducing the expression of MLH1 and that a decrease in MLH1 is associated with the recurrence of GBM.

Report

(4 results)
  • 2012 Annual Research Report   Final Research Report ( PDF )
  • 2011 Annual Research Report
  • 2010 Annual Research Report
  • Research Products

    (4 results)

All 2012 2011 2010

All Presentation (4 results)

  • [Presentation] MLH1発現低下とヒトglioma細胞のTMZ耐性獲得との関連2012

    • Author(s)
      新里能成
    • Organizer
      日本がん分子標的治療学会
    • Place of Presentation
      北九州(西日本総合展示場AIF3F)
    • Related Report
      2012 Annual Research Report
  • [Presentation] MLH1発現抑制とヒトglioma U251細胞のTMZ耐性獲得との関連2011

    • Author(s)
      新里能成
    • Organizer
      日本脳腫瘍学会
    • Place of Presentation
      下呂温泉(静岡)
    • Year and Date
      2011-11-28
    • Related Report
      2011 Annual Research Report
  • [Presentation] MLH1発現抑制とヒトglioma U251細胞のTMZ耐性獲得との関連2010

    • Author(s)
      新里能成
    • Organizer
      日本癌学会
    • Place of Presentation
      福岡国際会議場(福岡県福岡市)
    • Year and Date
      2010-10-28
    • Related Report
      2010 Annual Research Report
  • [Presentation] MLH1発現抑制とヒトglioma U251細胞のTMZ耐性獲得との関連2010

    • Author(s)
      新里能成
    • Organizer
      日本癌学会
    • Place of Presentation
      大阪国際会議場(大阪府大阪市)
    • Year and Date
      2010-09-23
    • Related Report
      2010 Annual Research Report

URL: 

Published: 2010-08-23   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi